Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A Pilot Study

Bousquet, Elodie, Beydoun, Talal, Zhao, Min, Hassan, Leila, Offret, Olivier, Behar-Cohen, Francine · 2013 · Retina

Abstract

In Brief Purpose: Based on experimental data showing that central serous chorioretinopathy could result from overactivation of mineralocorticoid receptor pathway in choroid vessels, the authors studied eplerenone, a mineralocorticoid receptor antagonist, as a potential treatment for chronic central serous chorioretinopathy. Methods: This nonrandomized pilot study included 13 patients with central serous chorioretinopathy of at least 4-month duration, treated with 25 mg/day of oral eplerenone for a week followed by 50 mg/day for 1 or 3 months. The primary outcome measure was the changes in central macular thickness recorded by optical coherence tomography, and the secondary outcomes included changes in foveal subretinal fluid (SRF) measured by OCT, in best-corrected visual acuity (BCVA) and the percentage of eyes achieving complete resolution of subretinal fluid during the treatment period. Results: Central macular thickness decreased significantly from 352 ± 139 μm at baseline to 246 ± 113 μm and 189 ± 99 μm at 1 and 3 months under eplerenone treatment (P < 0.05 and P < 0.01, respectively). At 3 months, the subretinal fluid significantly decreased compared with baseline subretinal fluid (P < 0.01) and best-corrected visual acuity significantly improved compared with baseline best-corrected visual acuity (P < 0.001). Conclusion: Eplerenone treatment was associated with a significant reduction in central macular thickness, subretinal fluid level, and an improvement in visual acuity. Randomized controlled trials are needed to confirm these encouraging results. This pilot study is the first clinical trial evaluating eplerenone, a mineralocorticoid receptor antagonist, as a potential treatment for chronic central serous chorioretinopathy. The results of this study suggest that eplerenone may be an effective and well-tolerated treatment, but larger randomized trials with longer follow-up are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318297a07a

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 212

Metadata

Authors
Bousquet, E., Beydoun, T., Zhao, M., Hassan, L., Offret, O., & Behar-Cohen, F.
Venue
Retina
Published
2013-11
Volume
33
Issue
10
Pages
2096-2102
ISSN
0275-004X (ISSN-L)
OpenAlex
W2009658202
Cited by
212
References
2
FWCI
18.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A Pilot Study. https://app.cochat.ai/papers/10.1097/iae.0b013e318297a07a
The paper
Bousquet, E., Beydoun, T., Zhao, M., Hassan, L., Offret, O., & Behar-Cohen, F. (2013). MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A Pilot Study. Retina. https://doi.org/10.1097/iae.0b013e318297a07a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.